Sai Parenteral’s Limited has opened its Initial Public Offering (IPO) today on March 24, 2026. The bidding window for Sai Parenteral’s IPO will be open from Tuesday, March 24, to Friday, March 27, 2026. The allotment process is expected to be finalised on March 30, 2026, and the shares will be listed on both BSE and NSE, with a tentative listing date of April 2, 2026.

Sai Parenteral’s Limited is a Hyderabad-based pharmaceutical manufacturing company engaged in the development, manufacturing, and supply of pharmaceutical formulations.

Sai Parenteral's IPO - Issue Details

Sai Parenteral's IPO is a book-building issue of ₹408.79 crore comprising a fresh issue of ₹285 crore and an offer for sale (OFS) of 0.32 crore equity shares, aggregating to ₹123.79 crore.

The IPO price band is fixed at ₹372 to ₹392 per share, and the minimum lot size required for an application is 38. The minimum investment required by retail investors is ₹14,896 (38 shares) based on the upper price.

Arihant Capital Markets Limited is the book-running lead manager, and Bigshare Services Private Limited is the registrar of the issue.

Explore other Upcoming IPOs on BSE and NSE.

Sai Parenteral's IPO Day 1 Subscription Status

[March 24, 2026, 11:33 AM]

On Day 1, Sai Parenteral's IPO saw a subscription of 0.01 times as per the NSE data on March 24, 2026, 11:33 a.m. The public issue was subscribed 0.01 times by the Retail Individual Investors (RIIs), 0.03 times by the Non Institutional Investors (NIIs) and 0 times by the Qualified Institutional Buyers (QIBs).

Utilisation of Proceeds

The Company will utilise the net proceeds from the fresh issue towards the following purposes:

Capacity expansion and upgradation of manufacturing facilities.
Establishment of a new R&D Centre.
Repayment/prepayment of certain outstanding borrowings.
Working capital requirements.
Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia).
General corporate purposes.

Check out newly Listed IPOs on BSE and NSE.

Sai Parenteral’s Limited GMP

As per media reports, the Grey Market Premium (GMP) of Sai Parenteral’s Limited is reported at 0.

About Sai Parenteral’s Limited

Sai Parenteral's Limited is engaged in the manufacturing and supply of pharmaceutical formulations. Its product portfolio spans multiple therapeutic areas, including cardiovascular, antidiabetic, antibiotic, gastroenterology, and dermatology, and includes dosage forms such as injectables, tablets, capsules, and liquid orals.

The company caters to a wide range of clients, including government institutions and pharmaceutical companies, and has a strong presence in the sterile injectables and critical care segments. It operates as an unlisted public company with manufacturing and R&D facilities in Telangana.

Financially, the company has witnessed steady growth. Revenue increased from around ₹97 crore in FY23 to about ₹163 - ₹164 crore in FY25, while profit after tax rose to approximately ₹14 crore - ₹15 crore.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here.

Do you like this edition?